In 98 patients with metastatic renal cell carcinoma and bone metastases, adding radium-223 to cabozantinib did not improve symptomatic skeletal event-free survival (median 16.7 v 17.6 months; sHR 1.46); the trial closed early after crossing an interim futility boundary.
RCTn = 98
McKay et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)